



Omega Pharma is perfectly on track for IPO of Arseus in 2008

Nazareth (Belgium), 8 February 2007 – Omega Pharma reconfirms that it remains the primary scenario to have Arseus run an autonomous course through an Initial Public Offering (IPO) in 2008.

To this end, the business-to-business organization of Omega Pharma has implemented the scheduled reorientation and restructurings in 2006. In spite of the often far-reaching measures in the restructuring year 2006, Arseus has achieved a turnover of EUR 277 million (-2% versus 2005). In the fourth quarter of 2006, Arseus again posted a sales increase of 5%. This demonstrates that Arseus is ready for 2007 – which was right from the start identified in this scenario as the reference year in anticipation of an IPO in 2008.

As mentioned in the press, the promising future of Arseus has attracted considerable interest from the financial world – both for an IPO and for possible alternative options. Omega Pharma has not taken any decision in this respect. The company has therefore not mandated any corporate banker, and is currently not considering this either.

Throughout 2007, Arseus will first demonstrate the value of its new business model. Arseus has everything needed to become over time the European consolidator in the currently fragmented market of products and services for healthcare professionals.

For more information, please contact:

Chris.Vanraemdonck@omega-pharma.be

0032/9/381.02.15 – 0032/499/58.55.31